The enteric nervous system III: A target for pharmacological treatment

Pharmacology and Toxicology

Volumn 93, Issue 1, 2003, Pages 1-13

  Hansen, Mark Berner ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ ANTAGONIST; BUSPIRONE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GONADORELIN DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; OCTREOTIDE; OPIATE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; CANCER; CARCINOGENICITY; COLON OBSTRUCTION; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; ESOPHAGUS ACHALASIA; FUTUROLOGY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HEART ARRHYTHMIA; HUMAN; INTESTINE FUNCTION; INTESTINE INNERVATION; ISCHEMIC COLITIS; NEUROENDOCRINE DISEASE; NEUROPATHY; PAIN; PRIORITY JOURNAL; SEIZURE; SEROTONIN RELEASE; SHORT SURVEY; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; URINE RETENTION;

ACETYLCHOLINE; ANIMALS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PAIN; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 0038786708     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2003.930101.x     Document Type: Short Survey

References (111)

1. Accarino, A. M., F. Azpiroz & J. R. Malagelada: Gut perception in humans is modulated by interacting gut stimuli. Amer. J. Physiol. Gastrointest. Liver Physiol. 2002, 282, G220-G225.
2. Ahn, J. & E. D. Ehrenpreis: Emerging treatments for irritable bowel syndrome. Expert. Opin. Pharmacother. 2002, 3, 9-21.
3. Akehurst, R. & E. Kaltenthaler: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001, 48, 272-282.
4. Atkinson, R. J. & J. O. Hunter: Role of diet and bulking agents in the treatment of IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 141-150.
5. Azpiroz, F.: Gastrointestinal perception: pathophysiological implications. Neurogastroenterol. Motil. 2002, 14, 229-239.
6. Bates, M. D.: Development of the enteric nervous system. Clin. Perinatol. 2002, 29, 97-114.
7. Bharucha, A. E., M. Camilleri, S. Haydock, I. Ferber, D. Burton, S. Cooper, D. Tompson, K. Fitzpatrick, R. Higgins & A. R. Zinsmeister: Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 2000, 47, 667-674.
8. Boeckxstaens, G. E., D. P. Hirsch, B. D. van den Elzen, S. H. Heisterkamp & G. N. Tytgat: Impaired drinking capacity in patients with functional dyspepsia: relationship with proximal stomach function. Gastroenterology 2001, 121, 1054-1063.
9. Borman, R. A., J. A. Carey, N. Day, N. S. Tilford & R. A. Coleman: Functional evidence that 5-HT2B receptors play a pivotal role in controlling motility in human colon. Gastroenterology 2001, 120, A138.
10. Bueno, L.: New and future drugs in nerve-gut dysfunction. Ital. J. Gastroenterol. Hepatol. 1999, 31, 794-801.
11. Bueno, L. & J. Fioramonti: Effects of inflammatory mediators on gut sensitivity. Can. J. Gastroenterol. 1999, 13, Suppl A, 42A-46A.
12. Bueno, L., J. Fioramonti, M. Delvaux & J. Frexinos: Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997, 112, 1714-1743.
13. Bueno, L., J. Fioramonti & R. Garcia-Villar: Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Amer. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G670-G676.
14. Bulat, R., C. Caldarelli & G. Tougas: Therapeutic utility of antispasmotics in IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 173-178.
15. Camilleri, M.: Management of the irritable bowel syndrome. Gastroenterology 2001a, 120, 652-668.
16. Camilleri, M.: Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist. Neurogastroenterol. Motil. 2001b, 13, 277-295.
17. Camilleri, M.: Serotonergic drugs: emerging therapies for IBS. In: Irritable bowel syndrome. Eds.:M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 179-190.
18. Camilleri, M., R. Heading & W. G. Thompson: Consensus report: clinical perspectives, mechanisms, diagnosis and mangement of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2002, 16, 1407-1430.
19. Cervero, F. &J. M. Laird: Visceral pain. Lancet 1999, 353, 2145-2148.
20. Clouse, R. E. & P. J. Lustman: Antidepressants for IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 161-172.
21. Coelho, A. M., L. Jacob, J. Fioramonti & L. Bueno: Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J. Pharm. Pharmacol. 2001, 53, 1419-1426.
22. Corsetti, M. & J. Tack: Mechanisms of functional dyspepsia and its relation to IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Science Limited, Edinburgh, 2002, pp. 117-127.
23. Cremonini, F., S. Delgado-Aros & M. Camilleri: Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol. Motil. 2003, 15, 79-86.
24. De Ponti, F. & M. Tonini: Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001, 61, 317-332.
25. Delvaux, M., D. Louvel, E. Lagier, B. Scherrer, J. L. Abitbol & J. Frexinos: The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999, 116, 38-45.
26. Der Ohe, M. R., M. Camilleri & L. K. Kvols: A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994, 106, 1184-1189.
27. Drossman, D. A.: Irritable bowel syndrome: how far do you go in the workup? Gastroenterology 2001, 121, 1512-1515.
28. Fidelholtz, J., W. Smith, J. Rawls, Y. Shi, A. Zack, P. Ruegg & M. Lefkowitz: Safety and tolerability of tegaserod in patients with irritabile bowel syndrome and diarrhea symptoms. Amer. J. Gastroenterol 2002, 97, 1176-1181.
29. Fiorica-Howells, E., L. Maroteaux & M. D. Gershon: Serotonin and the 5-HT(2B) receptor in the development of enteric neurons. J. Neurosci 2000, 20, 294-305.
30. Fiorucci, S. & E. Distrutti: Role of PAR2 in pain and inflammation. Trends Pharmacol. Sci. 2002, 23, 153-155.
31. Galligan, J. J.: Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav. Brain Res. 1996, 73, 199-201.
32. Galligan, J. J.: Ligand-gated ion channels in the enteric nervous system. Neurogastroenterol. Motil. 2002, 14, 611-623.
33. Gao, C., P. Petersen, W. Liu, L. Arendt-Nielsen, A. M. Drewes & H. Gregersen: Sensory-motor responses to volume-controlled duodenal distension. Neurogastroenterol. Motil 2002, 14, 365-374.
34. Gaster, L. M. & F. D. King: Serotonin 5-HT3 and 5-HT4 receptor antagonists. Med. Res. Rev. 1997, 17, 163-214.
35. Geboes, K. & S. Collins: Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol. Motil. 1998, 10, 189-202.
36. Gershon, M. D. V. Genes: Lineages & tissue interactions in the development of the enteric nervous system. Amer. J. Physiol. 1998, 275, G869-G873.
37. Gershon, M. D.: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 1999, 13 Suppl. 2, 15-30.
38. Gershon, M. D.: Importance of serotonergic mechanisms in gastrointestinal motility and sensation. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 95-116.
39. Giamberardino, M. A.: Recent and forgotten aspects of visceral pain. Eur. J. Pain 1999, 3, 77-92.
40. Glatzle, J., C. Sternini, C. Robin, T. T. Zittel, H. C. Wong, J. R. Reeve, Jr. & H. E. Raybould: Expression of 5-HT3 receptors in rat gastrointestinal tract. Gastroenterology 2002, 123, 217-226.
41. Goyal, R. K. & I. Hirano: The enteric nervous system. New Engl. J. Med. 1996, 334, 1106-1115.
42. Grossi, L., A. F. Ciccaglione & L. Marzio: Effect of the 5-HT1 agonist sumatriptan on oesophageal motor pattern in patients with effective oesophageal motility. Neurogastroenterol. Motil. 2003, 15, 9-14.
43. Grundy, D.: Towards a reduction of rectal pain? Neurogastroenterol. Motil. 2002, 14, 217-218.
44. Gunthrope, M. J., C. D. Benham, A. Randall & J. B. Davis: The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci. 2002, 23, 183-191.
45. Guthrie, E. & P. J. Whorwell: Psychotherapy and hypnotherapy. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 151-160.
46. Hansen, M. B. & E. Skadhauge: Signal transduction pathways for serotonin as an intestinal secretagogue. Comp. Biochem. Physiol. A Physiol. 1997, 118, 283-290.
47. Hansen, M. B.: Small intestinal manometry. Physiol. Res. 2002, 51, 541-556.
48. Hansen, M. B.: The enteric nervous system I: Organisation and classification. Pharmacology Toxicology 2003a, 92, 105-113.
49. Hansen, M. B.: The enteric nervous system II: Gastrointestinal functions. Pharmacology Toxicology 2003b, 92, 249-257.
50. Hansen, M. B.: Neurohumoral control of gastrointestinal motility. Physiol. Res. 2003c, 52, 1-30.
51. Hasler, W. L.: Serotonin receptor physiology: relation to emesis. Dig. Dis. Sci. 1999, 44, 108S-113S.
52. Henrichs, I. & W. M. Teller: Pathophysiology of gastrointestinal hormones. Implications for paediatrics. Eur. J. Pediatr. 1980, 135, 3-11.
53. Hicks, G. A., P. A. Lynn, D. Jenkins & P. P. A. Humphrey: 5-HT3 receptor mediated excitation of colonic afferent endings: functional and anatomical relations. Gastroenterology 2001, 120, A6.
54. Hillsley, K., C. Eeckhout & D. Grundy: Cilansetron acts at its site of absorption to antagonize the sensitivity of mesenteric afferent fibres to 5-hydroxytryptamine in the rat jejunum. Neurosci. Lett. 2000, 278, 137-140.
55. Holzer, P.: Sensory neurone responses to mucosal noxae in the upper gut: relevance to mucosal integrity and gastrointestinal pain. Neurogastroenterol. Motil. 2002, 14, 459-475.
56. Hou, X. H., L. R. Zhu, W. Qian & J. D. Chen: Role of 5-HT in gastric, hypersensitivity. Neurogastroenterol. Mot. 2002, 14, 430 (abstract).
57. Hoyer, D. & G. Martin: 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36, 419-428.
58. Iwase, K., B. M. Evers, M. R. Hellmich, H. J. Kim, S. Higashide, D. Gully & C. M. Townsend: Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 1997, 79, 1787-1793.
59. Janssen, P., N. H. Prins, A. L. Meulemans & R. Lefebvre: 5-HT7 receptors mediate canine stomach relaxation, an in vivo study. Neurogastroenterol. Motil. 2002, 14, 571-571.
60. Jensen, J. A., R. E. Carroll & R. V. Benya: The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001, 22, 689-699.
61. Kapur, R. P.: Hirschsprung disease and other enteric dysganglionoses. Crit Rev. Clin. Lab Sci. 1999, 36, 225-273.
62. Kellow, J. E., M. Delvaux, F. Azpiroz, M. Camilleri, E. M. Quigley & D. G. Thompson: Principles of applied neurogastroenterology: physiology/motility-sensation. Gut 1999, 45, Suppl 2, II17-II24.
63. Kirchgessner, A. L., M. T. Liu, J. R. Raymond & M. D. Gershon: Identification of cells that express 5-hydroxytryptamine 1A receptors in the nervous systems of the bowel and pancreas. J. Comp. Neurol. 1996, 364, 439-455.
64. Kirkup, A. J., A. M. Brunsden & D. Grundy: Receptors and transmission in the brain-gut axis: potential for novel therapies. I. Receptors on visceral afferents. Amer. J. Physiol. Gastrointest. Liver Physiol. 2001, 280, G787-G794.
65. Kreis, M. E., M. Kasparek, A. Vogt, H. D. Becker, T. T. Zittel & E. C. Jehle:Postoperative colonic motility is increased and oral food intake facilitated following treatment with 5-HT receptor antagonist tropisetron in patient after colo-rectal surgery. Gastroenterology 2001, 120, A473.
66. Kurian, S. S., G. L. Ferri, J. De Mey & J. M. Polak: Immunocytochemistry of serotonin-containing nerves in the human gut. Histochemistry 1983, 78, 523-529.
67. Ladabaum, U. & D. Gliddin: Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol. Motil. 2002, 14, 395-401.
68. Linden, D. R., P. L. Moses, C. Barron, M. D. Crowell: Colonic serotonin signaling is altered in IBD and IBS. Neurogastroenterol. Mot. 2002, 14, 436 (abstract).
69. Liu, H.-X. & T. Hökfelt: The participation of galanin in pain processing at the spinal level. Trends Pharmacol. Sci. 2002, 23, 468-474.
70. Longstreth, G. F.: Clinical diagnosis of IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Science Limited, Edinburgh, 2002, pp. 1-11.
71. Magro, F., M. A. Vieira-Coelho, S. Fraga, M. P. Serrao, F. T. Veloso, T. Ribeiro & P. Soares-da-Silva. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig. Dis. Sci. 2002, 47, 216-224.
72. Malagelada, J. R.: Clinical pharmacology models of irritable bowel syndrome. Aliment. Pharmacol. Ther. 1999, 13, Suppl 2, 57-64.
73. Manes, G., J. E. Dominguez-Munoz, A. Leodolter & P. Malfertheiner: Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans. Dig. Liver Dis. 2001, 33, 407-413.
74. Maoret, J. J., Y. Anini, C. Rouyer-Fessard, D. Gully & M. Laburthe: Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int. J. Cancer 1999, 80, 448-454.
75. Mayer, E. A. & G. F. Gebhart: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994, 107, 271-293.
76. Meijers, C., M. Hosgor, R. Keijzer & P. Lohman: Cellular and molecular mechanisms involved in the development of the enteric nervous system. Eur. J. Morphol. 1999, 37, 227-232.
77. Mertz, H.: Altered CNS processing of visceral pain in IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Science Limited, Edinburgh, 2002, pp. 55-68.
78. Meyer, T. & U. Brinck: Differential distribution of serotonin and tryptophan hydroxylase in the human gastrointestinal tract. Digestion 1999, 60, 63-68.
79. Michel, K., S. Bischoff & M. Schemann: Serotonin excites neurons in the human submucosal plexus. Neurogastroenterol. Motil. 2002, 14, 574.
80. Miwa, J., H. Echizen, K. Matsueda & N. Umeda: Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001, 63, 188-194.
81. Muller-Lissner, S. A., I. Fumagalli, K. D. Bardhan, F. Pace, E. Pecher, B. Nault & P. Ruegg: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. 2001, 15, 1655-1666.
82. Newgreen, D. & H. M. Young: Enteric nervous system: development and developmental disturbances. Part 1 and 2. Pediatr. Dev. Pathol. 2002, 5, 224-247.
83. Pacher, P., Z. Ungvari, V. Kecskemeti, T. Friedmann & S. Furst: Serotonin reuptake inhibitors fluoxetine and citalopram relax intestinal smooth muscle. Can. J. Physiol. Pharmacol. 2001, 79, 580-584.
84. Pan, H. & M. D. Gershon: Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestine. J. Neurosci. 2000, 20, 3295-3309.
85. Perko, M. J.: Duplex ultrasound for assessment of superior mesenteric artery blood flow. Eur. J. Vasc. Endovasc. Surg. 2001, 21, 106-117.
86. Petersen, P., C. Gao, P. Rossel, P. Qvist, L. Arendt-Nielsen, H. Gregersen & A. M. Drewes: Sensory and biomechanical responses to distension of the normal human rectum and sigmoid colon. Digestion 2001, 64, 191-199.
87. Poynard, T., C. Regimbeau & Y. Benhamou: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2001, 15, 355-361.
88. Rozengurt, E. V.: Gastrointestinal peptide signaling through tyrosine phosphorylation of focal adhesion proteins. Amer. J. Physiol. 1998, 275, G177-G182.
89. Saragovi, H. U. & K. Gehring: Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol. Sci. 2000, 21, 93-98.
90. Schikowski, P., M. Thewiben, J. R. Mathias, H.-G. Ross & P. Enck: Serotonin type-4 receptors modulate the sensitivity of intramural mechanreceptive afferents of the cat rectum. Neurogastroenterol. Motil. 2002, 14, 221-227.
91. Schneider, J., E. C. Jehle, M. J. Starlinger, M. Neunlist, K. Michel, S. Hoppe & M. Schemann: Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. Neurogastroenterol. Motil. 2001, 13, 255-264.
92. Seretis, E., A. Gavrill, N. Agnantis, V. Golematis & I. E. Voloudakis-Battakis: Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumors of the colon. Ultrastruct. Pathol. 2001, 25, 445-454.
93. Shanahan, F.: Enteric neuropathophysiology and inflammatory bowel disease. Neurogastroenterol. Motil. 1998, 10, 185-187.
94. Small, P. K., M. A. Loudon, C. M. Hau, N. Noor & F. C. Campbell: Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand. J. Gastroenterol. 1997, 32, 39-47.
95. Smith, A. M. & S. A. Watson: Review article: gastrin and colorectal cancer. Aliment. Pharmacol. Ther. 2000, 14, 1231-1247.
96. Spiller, R. C.: Post-infectious IBS. In: Irritable bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. WB Saunders, Elsevier Sciences Limited, Edinburgh, 2002, pp. 85-96.
97. Steens, J., P. J. Van der Schaar, C. Penning, J. Brussee & A. A. M. Masclee: Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol. Motil. 2002, 14, 241-247.
98. Steinbach, G.: The effect of celecoxib, a cyclooxygenase-2 inhibitor in familiar adenomatous polyposis. New Engl. J. Med. 2000, 42, 1946-1952.
99. Su, X., V. Julia & G. F. Gebhart: Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J. Neurophysiol. 2000, 83, 963-970.
100. Subbaramaiah, K. & A. J. Dannenberg: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2002, 24, 96-102.
101. Tack, J., P. Caenepeel, B. Fischler, H. Piessevaux & J. Janssens: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121, 526-535.
102. Tack, J., H. Piessevaux, B. Coulie, B. Fischler, V. De Gucht & J. B. Jansen: A placebo-controlled trial of buspirone, a fundus relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology 1999, 116, A325.
103. Talley, N. J.: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol. Ther. 1992, 6, 273-289.
104. Talley, N. J., M. Verlinden, W. Snape, J. A. Beker, R Ducrotte, A. Dettmer, H. Brinkhoff, E. Eaker, G. Ohning, P. B. Miner, J. R. Mathias, I. Fumagalli, D. Staessen & R. J. Mack: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 2000, 14, 1653-1661.
105. Thompson, D. G.: A world-view of IBS. In: Irritabile bowel syndrome. Eds.: M. Camilleri and R. C. Spiller. W.B. Saunders, Elsevier Science Limited, Edinburgh, 2002, pp. 17-26.
106. Thun, M. J.: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
107. Vanhoenacker, P., G. Haegeman & J. E. Leysen: 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol. Sci. 2000, 21, 70-77.
108. Von Boyen, G. B., O. M. Von der, H. J. Krammer & M. V. Singer: Submucosal hypoganglionosis causing chronic idiopathic intestinal pseudo-obstruction. Indian J. Gastroenterol. 2002, 21, 29-30.
109. Watson, M. E., L. Lacey, S. Kong, A. R. Northcutt, D. McSorley, B. Hahn & A. W. Mangel: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Amer. J. Gastroenterol. 2001, 96, 455-459.
110. Watson, S. A. & A. D. Gilliam: G17DT-a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert. Opin. Biol. Ther. 2001, 1, 309-317.
111. Wood, J. D.: Enteric nervous system, serotonin & the irritable bowel syndrome. Curr. Opin. Gastroenterol. 2001, 17, 91-97.